CLL-FRAIL Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL (Aktiv)
iVAC-XS15-CLL01 Personalized Multi-peptide Vaccination in CLL Patients (Aktiv)
Erstlinie
CLL-RT1 Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation (Aktiv)
CLL2-BCG A prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 (obinutuzumab) and CAL-101 (idelalisib) followed by CAL-101 and GA101 maintenance in CLL patients (CLL2-BCG-trial of the GCLLSG) (Aktiv)
iVAC-L-CLL01 Patienten individualisierte Multi-Peptid Vakzine in Kombination mit Lenalidomid nach Erstlinientherapie der CLL (Aktiv)
Zweitlinie oder später
67856633LYM1001 A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (Aktiv)
BO43243 Eine offene, multizentrische Phase-Ib-Studie zur Beurteilung der Sicherheit, Wirksamkeit und Pharmakokinetik von Mosunetuzumab bei Patienten mit rezidivierter oder refraktärer chronischer lymphatischer Leukämie (Aktiv)
BeliVeR Phase-II-Studie bei rezidivierter oder refraktärer chronischer lymphatischer Leukämie zur Evaluation der Kombination von Belimumab mit Rituximab und Venetoclax Phase-II-Studie mit Belimumab in Kombination mit Rituximab/Venetoclax bei Patienten mit refraktärer oder rezidivierender chronischer lymphatischer Leukämie - BeliVeR (Aktiv)
CLL2-BAAG Evaluation of a treatment with bendamustine, followed by obinutuzumab, acalabrutinib and venetoclax in patients with relapsed chronic lymphocytic leukemia (Aktiv)
CLL2-BCG A prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 (obinutuzumab) and CAL-101 (idelalisib) followed by CAL-101 and GA101 maintenance in CLL patients (CLL2-BCG-trial of the GCLLSG) (Aktiv)
CYTB323A12101 Phase I/II, open label, multicenter study of rapcaptagene autoleucel in adult patients with CLL/SLL, 3L+ DLBCL, ALL and 1L HR LBCL (Aktiv)
GC-LTFU-001 Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells (Aktiv)
GS-US-401-2076_CLLRUmbrella2 Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (GS-4059) and Entospletinib With and Without Obinutuzumab in CLL (Aktiv)
LOXO-BTK-20022 (#1381) A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-322) (Aktiv)
REGN1979-HM-1333 This is an open-label, multi-center, dose escalation study of REGN1979 administered as an IV (intravenous) infusion. This phase 1 study will investigate the safety and tolerability of REGN1979 in patients with Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (Aktiv)